Curevac is trying to restart staff

Curevac boss Franz-Werner Haas in August 2020 on the video facade of the Nasdaq in Times Square

The company’s share price has plummeted since its IPO.

(Photo: dpa)

Frankfurt At the biotech company Curevac, another change in leadership is apparently in the offing. According to information from the Handelsblatt from the industry, the Tübingen-based company, which failed last year with the development of a Covid vaccine, is now intensively on the lookout for a new CEO who is to succeed the previous company boss Franz-Werner Haas in the coming year.

Haas’ contract was extended by another year until mid-2023 at the most recent annual general meeting. The company itself does not provide any information on further planning of the board positions, as does the main shareholder, Dievini Hopp Biotech Holding, in which SAP founder Dietmar Hopp has bundled his biotech commitments.

Read on now

Get access to this and every other article in the

Web and in our app free of charge for 4 weeks.

Continue

Read on now

Get access to this and every other article in the

Web and in our app free of charge for 4 weeks.

Continue

source site-17